{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:50:45Z","timestamp":1791327045881,"version":"4.3.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T00:00:00Z","timestamp":1575331200000},"content-version":"vor","delay-in-days":2527,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"U01","award":["CA099168-01"],"award-info":[{"award-number":["CA099168-01"]}]},{"name":"NIH R01","award":["CA113448"],"award-info":[{"award-number":["CA113448"]}]},{"name":"Head and Neck SPORE","award":["P50"],"award-info":[{"award-number":["P50"]}]},{"name":"Head and Neck SPORE","award":["CA097190-06"],"award-info":[{"award-number":["CA097190-06"]}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"crossref","award":["CA 87718"],"award-info":[{"award-number":["CA 87718"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"crossref"}]},{"name":"NCI & ECOG YIA"},{"name":"Genentech and Imclone Systems Incorporated"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1093\/annonc\/mds245","type":"journal-article","created":{"date-parts":[[2012,8,16]],"date-time":"2012-08-16T20:36:55Z","timestamp":1345149415000},"page":"220-225","source":"Crossref","is-referenced-by-count":132,"title":["Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck"],"prefix":"10.1016","volume":"24","author":[{"given":"A.","family":"Argiris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.P.","family":"Kotsakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Hoang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.P.","family":"Worden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Savvides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.K.","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Gyanchandani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"G.R.","family":"Blumenschein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.X.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.R.","family":"Grandis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.M.","family":"Harari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.S.","family":"Kies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mds245_bb0010","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(08)60728-X","article-title":"Head and neck cancer","volume":"371","author":"Argiris","year":"2008","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mds245_bb0015","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1002\/cncr.20640","article-title":"Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck","volume":"101","author":"Argiris","year":"2004","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mds245_bb0020","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1200\/JCO.1992.10.2.257","article-title":"A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck","volume":"10","author":"Jacobs","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds245_bb0025","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1200\/JCO.2005.05.3348","article-title":"Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck","volume":"24","author":"Colevas","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds245_bb0030","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1200\/JCO.1992.10.8.1245","article-title":"Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study","volume":"10","author":"Forastiere","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds245_bb0035","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","article-title":"Platinum-based chemotherapy plus cetuximab in head and neck cancer","volume":"359","author":"Vermorken","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mds245_bb0040","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2006.06.7447","volume":"25","author":"Vermorken","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds245_bb0045","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1001\/jama.298.1.70","article-title":"Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas","volume":"298","author":"Karamouzis","year":"2007","journal-title":"JAMA"},{"key":"10.1093\/annonc\/mds245_bb0050","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1517\/14712590902817817","article-title":"Bevacizumab: current indications and future development for management of solid tumors","volume":"9","author":"Jenab-Wolcott","year":"2009","journal-title":"Expert Opin Biol Ther"},{"key":"10.1093\/annonc\/mds245_bb0055","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/JCO.2007.14.9930","article-title":"Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study","volume":"26","author":"Saltz","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds245_bb0060","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mds245_bb0065","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa021491","article-title":"A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer","volume":"349","author":"Yang","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mds245_bb0070","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1200\/JCO.2010.33.3591","article-title":"Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer","volume":"29","author":"Argiris","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds245_bb0075","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1158\/1541-7786.MCR-06-0404","article-title":"The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents","volume":"5","author":"Tabernero","year":"2007","journal-title":"Mol Cancer Res"},{"key":"10.1093\/annonc\/mds245_bb0080","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.ijrobp.2003.09.091","article-title":"Acquired resistance to EGFR inhibitors: mechanisms and prevention strategies","volume":"58","author":"Viloria-Petit","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1093\/annonc\/mds245_bb0085","first-page":"2554","article-title":"ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase","volume":"62","author":"Hirata","year":"2002","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mds245_bb0090","first-page":"1546","article-title":"Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase","volume":"9","author":"Ciardiello","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mds245_bb0095","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1097\/MLG.0b013e318031055e","article-title":"Concurrent cetuximab and bevacizumab therapy in a murine orthotopic model of anaplastic thyroid carcinoma","volume":"117","author":"Prichard","year":"2007","journal-title":"Laryngoscope"},{"key":"10.1093\/annonc\/mds245_bb0100","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/sj.bjc.6604429","article-title":"Combined effects of bevacizumab with erlotinib and irradiation: a preclinical study on a head and neck cancer orthotopic model","volume":"99","author":"Bozec","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mds245_bb0105","first-page":"3570","article-title":"Enhanced antiangiogenic therapy of squamous cell carcinoma by combined endostatin and epidermal growth factor receptor-antisense therapy","volume":"8","author":"Li","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mds245_bb0110","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1470-2045(09)70002-6","article-title":"Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I\/II study","volume":"10","author":"Cohen","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mds245_bb0115","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1158\/1078-0432.CCR-10-0568","article-title":"HGF rescues colorectal cancer cells from EGFR inhibition via MET activation","volume":"17","author":"Liska","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mds245_bb0120","doi-asserted-by":"crossref","first-page":"9479","DOI":"10.1158\/0008-5472.CAN-08-1643","article-title":"Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations","volume":"68","author":"Yano","year":"2008","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mds245_bb0125","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1200\/JCO.2005.02.2574","article-title":"Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma","volume":"24","author":"Motzer","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds245_bb0130","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1200\/JCO.2006.07.8170","article-title":"Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors","volume":"25","author":"Rosen","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds245_bb0135","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1016\/S0002-9440(10)64325-8","article-title":"Distinct role of fibroblast growth factor-2 and vascular endothelial growth factor on tumor growth and angiogenesis","volume":"162","author":"Giavazzi","year":"2003","journal-title":"Am J Pathol"},{"key":"10.1093\/annonc\/mds245_bb0140","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.cytogfr.2005.01.004","article-title":"Fibroblast growth factor\/fibroblast growth factor receptor system in angiogenesis","volume":"16","author":"Presta","year":"2005","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1093\/annonc\/mds245_bb0145","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.ccr.2005.09.005","article-title":"Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors","volume":"8","author":"Casanovas","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1093\/annonc\/mds245_bb0150","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1016\/j.ijrobp.2005.11.017","article-title":"Augmentation of radiation response with the vascular targeting agent ZD6126","volume":"64","author":"Hoang","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1093\/annonc\/mds245_bb0155","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mds245_bb0160","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1007\/s10637-011-9732-3","article-title":"Phase I and pharmacokinetic study of dasatinib and cetuximab in patients with advanced solid malignancies","volume":"30","author":"Argiris","year":"2012","journal-title":"Invest New Drugs"},{"key":"10.1093\/annonc\/mds245_bb0165","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1158\/1078-0432.CCR-07-1543","article-title":"Immunohistochemical analysis of phosphotyrosine signal transducer and activator of transcription 3 and epidermal growth factor receptor autocrine signaling pathways in head and neck cancers and metastatic lymph nodes","volume":"14","author":"Seethala","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mds245_bb0170","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1158\/1078-0432.CCR-08-2068","article-title":"Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells","volume":"15","author":"Benavente","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mds245_bb0175","first-page":"5501","article-title":"BIBW 2992 versus cetuximab in patients with metastatic or recurrent head and neck cancer (SCCHN) after failure of platinum-containing therapy with a cross-over period for progressing patients: preliminary results of a randomized, open-label phase II study","volume":"28","author":"Seiwert","year":"2010","journal-title":"ASCO Meeting Abstracts"},{"key":"10.1093\/annonc\/mds245_bb0180","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1200\/JCO.2004.06.075","article-title":"Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck","volume":"22","author":"Soulieres","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds245_bb0185","doi-asserted-by":"crossref","first-page":"4504","DOI":"10.1002\/cncr.24528","article-title":"Docetaxel and irinotecan in recurrent or metastatic head and neck cancer: a phase 2 trial of the Eastern Cooperative Oncology Group","volume":"115","author":"Argiris","year":"2009","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mds245_bb0190","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1200\/JCO.2008.19.8135","article-title":"A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer","volume":"27","author":"Hecht","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds245_bb0195","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1056\/NEJMoa0808268","article-title":"Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer","volume":"360","author":"Tol","year":"2009","journal-title":"N Engl J Med"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419370413?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419370413?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/24\/1\/220\/13789118\/mds245.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T03:23:34Z","timestamp":1624505014000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419370413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["S0923753419370413"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mds245","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717954885.793461177","asserted-by":"object"}]},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1]]}}}